Pasithea Therapeutics Corp.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $486,559 | $15,062 |
| Gross profit | — | — | — | — | -$2,213 |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$12.6M | -$4.5M |
| Cost of revenue | — | — | — | $113,195 | $17,275 |
| Cash from operations | -$15.2M | -$13.9M | -$12.8M | -$14.6M | -$3.2M |
| Capital expenditure | — | — | $34,301 | $107,101 | $21,503 |
| Free cash flow | — | — | -$12.8M | -$14.7M | -$3.2M |
| Share repurchases | — | — | $3.7M | $3.2M | — |
| Impairments | $4.2M | — | — | — | — |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M |
Shares outstanding 33.4M · Free float 64.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.